Author Archives: Vijaya Iyer, PhD

Adempas Therapy Improves Blood Flow in Sildenafil-treated CTEPH Patients, Study Says

Adempas therapy significantly improves lung and heart function in patients with chronic thromboembolic pulmonary hypertension (CTEPH) previously treated off-label with sildenafil, according to a Polish study. The study reporting the findings, “Sequential treatment with sildenafil and riociguat in patients with persistent or inoperable chronic thromboembolic pulmonary hypertension improves…

Bayer Launches ‘MyMentor’ Program, Connecting PAH or CTEPH Patients to Others with Firsthand Experience

Patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) and their caregivers can now access myMentor, a U.S. support program established by Bayer. The company launched the program at the International PH Conference and Scientific Sessions that recently concluded in Orlando, Florida, and was organized by…

Vivus’ Experimental PAH Therapy VI-0106 Shows Potential in Phase 1 Study

Vivus Biopharmaceuticals’ investigative therapy VI-0106 for pulmonary arterial hypertension (PAH) showed a favorable pharmacokinetic profile in healthy volunteers in a Phase 1 trial. Pharmacokinetics refers to how a medication is absorbed, distributed, metabolized, and eliminated from the body. VI-0106 is a soft gel formulation of tacrolimus, an immunosuppressant under…

Surgical Removal of Blood Clots Reverses PH But Not Sleep Issues in CTEPH Patients, Study Finds

Surgery to remove blood clots from the arteries improves pulmonary hypertension (PH) symptoms but not underlying sleep disorders in patients with chronic thromboembolic pulmonary hypertension (CTEPH), according to a study. The study, “Chronic thromboembolic pulmonary hypertension: Reversal of pulmonary hypertension but not sleep-disordered breathing following…

Canada Expands Public Health Coverage for PAH Therapy Uptravi

Five Canadian provinces, Alberta, Ontario, Saskatchewan, Manitoba, and Newfoundland and Labrador, have approved public health insurance coverage for Uptravi (selexipag), a pulmonary arterial hypertension (PAH) therapy developed by Actelion. Quebec was the first province to approve public funding for Uptravi in Canada, in March 2018. The…